The Economic Value of Vaccines
Each $1 invested in boosting access to adult immunisation can deliver more than $3.50 in benefits
Investment in adult vaccination can be Australia’s superpower. Vaccines reduce demands on the health system, increase productivity and benefit the economy.
“Prevention: A Productivity Superpower” assesses the economic value of vaccines. It demonstrates the value of vaccines in boosting productivity while reducing a range of government and social costs: across health, tax, aged care, disability and carer support.
GSK commissioned Evaluate Consulting to explore the cost-effectiveness of those vaccines recommended to Australian adults in the Australian Immunisation Handbook, but not fully funded by the Government.
As the population ages, vaccinations become even more valuable by helping Australians to live well for longer. Preventing disease is integral to Australia’s future economic resilience, as a healthy ageing population positively impacts workforce productivity, participation, and economic growth.
